Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis

There are conflicting results concerning an association between Chlamydia pneumoniae and MS (multiple sclerosis). In the present study, we investigated a possible therapeutic option with antibiotics. In our randomized, placebo-controlled double-blind study, 28 patients with the confirmed diagnosis o...

Full description

Saved in:
Bibliographic Details
Published in:Infection 2006-12, Vol.34 (6), p.342-344
Main Authors: Woessner, R, Grauer, M T, Frese, A, Bethke, F, Ginger, T, Hans, A, Treib, J
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - administration & dosage
Antibiotics
Autoimmune diseases
Bacterial diseases
Chlamydophila pneumoniae
Double-Blind Method
Drug Administration Schedule
Humans
Multiple Sclerosis - drug therapy
Multiple Sclerosis - etiology
Pilot Projects
Roxithromycin - administration & dosage
Sexually transmitted diseases
STD
Treatment Failure
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are conflicting results concerning an association between Chlamydia pneumoniae and MS (multiple sclerosis). In the present study, we investigated a possible therapeutic option with antibiotics. In our randomized, placebo-controlled double-blind study, 28 patients with the confirmed diagnosis of MS [61% relapsing-remitting MS (RR-MS), 32% secondary chronic-progressive MS (SP-MS) and 7% primary chronic progressive MS (PP-MS)] were treated over a time period of 12 months with three cycles of a 6-week oral antibiotic therapy with roxithromycin (300 mg per day) or placebo. No significant differences were observed in patients with RR-MS regarding the expanded disability status scale (EDSS) and the relapse rate when comparing treatment with roxithromycin and placebo. Our study shows that the patients with MS do not profit from a long-term antibiotic treatment with roxithromycin compared to placebo treatment. A causative connection between bacterial infections with C. pneumonia and MS therefore does seem very unlikely.
ISSN:0300-8126
1439-0973
DOI:10.1007/s15010-006-5114-8